Apnimed to Present Phase 3 Sleep Apnea Data at CHEST 2026 Meeting
Apnimed, Inc. (APMD) will present five scientific abstracts at the American College of Chest Physicians CHEST 2026 Annual Meeting in Phoenix, Arizona, scheduled for October 18 to 21. The presentations include three abstracts from the Phase 3 development program for AD109, an investigational oral medication for obstructive sleep apnea, featuring two late-breaking presentations alongside real-world studies on disease burden.
Current obstructive sleep apnea treatments rely heavily on medical devices or invasive surgical procedures. AD109 combines aroxybutynin and atomoxetine into a once-daily pill taken at bedtime to target the underlying neuromuscular causes of airway collapse. Demonstrating clinical efficacy and safety across its completed Phase 3 SynAIRgy and LunAIRo trials is crucial for establishing an oral drug therapy alternative in sleep medicine.
Investors and healthcare providers will monitor the upcoming conference panel discussion on the Phase 3 trial results and additional patient-reported outcomes. Further attention will focus on regulatory progress, as Apnimed has submitted a new drug application to the U.S. Food and Drug Administration, which carries a target PDUFA action date of February 28, 2027.
Key points
- Apnimed will present five abstracts at the CHEST 2026 Annual Meeting taking place October 18 through 21 in Phoenix, Arizona.
- Three abstracts focus on Phase 3 data for AD109, an oral medication for obstructive sleep apnea, including two late-breaking presentations.
- AD109 is a once-daily bedtime combination pill designed to treat the root neuromuscular causes of upper airway collapse during sleep.
- The U.S. Food and Drug Administration is reviewing the new drug application for AD109 with a PDUFA date of February 28, 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is Apnimed presenting at CHEST 2026?
Apnimed is presenting five abstracts at CHEST 2026, including three covering Phase 3 clinical data for its obstructive sleep apnea drug candidate AD109 and two on real-world disease burden.
What is AD109 and how does it work?
AD109 is an investigational once-daily oral pill combining aroxybutynin and atomoxetine designed to treat obstructive sleep apnea by targeting the neuromuscular causes of airway collapse during sleep.
When is the FDA decision date for AD109?
The U.S. Food and Drug Administration has set a target PDUFA action date of February 28, 2027, for its review of Apnimed's new drug application for AD109.